LAG3 and melanoma: The putative association described here is supported by results reported by Shen et al., which identified a pre-treatment peripheral LAG+ immunotype that was defined in part by a LAG-3+ CD8 T cell population and predicted poorer outcomes to ICI in patients with melanoma and urothelial carcinoma (61).